Amgen Signs US$2 B Licensing Agreement with Synaffix for Next-Generation ADCs
By Lalit Mishra & Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)
Published: 3 Feb-2023
DOI: 10.3833/pdr.v2023.i2.2762 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Demonstrating its continued interest in antibody-drug conjugate (ADC) therapeutics, Amgen has agreed to pay up to US$2 B for exclusive access to Synaffix's ADC technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS